Gsk Share Discussion Threads

[tradermichael] 12/12/2017 10:24

Anyway, IN @ 1312.835 ....... ;0)

[tradermichael] 12/12/2017 10:22

Correct - its not what she's doing, its what she said she might do!

[romeike] 12/12/2017 10:19

Emma W making the right moves. Just wish she'd stay clear of analysts.

[tradermichael] 12/12/2017 09:55

Its a L O N G climb back up, even longer if Emma blunders again ..... ;0)

[mani2013] 12/12/2017 08:22

BUY Signal on the 60 min (at last !!). 60m Chart downtrend broken.

DAILY is still in downtrend and could potentially create a swing point for the downtrend to continue in the next few days.

Situation is still precarious for LONG TERM investors. Enter on pullbacks and don't forget to use stops !

Please DYOR :)

[cwa1] 12/12/2017 07:59

Promising data for GSK2857916 at ASH meeting

[alphorn] 11/12/2017 13:26

Agree, would take great care. Have not followed IMM - they are doing pivotal PIII trials?

[romeike] 11/12/2017 13:24

IMM been hyped to death here and elsewhere - going to be one hell of a crash if clinical trials fall flat

[top tips] 11/12/2017 11:38

ImmuPharma (IMM) get Phase 3 results for their lupus drug Lupuzor in Jan 2018, and indications from the Phase 2b results and ongoing excellent safety and tolerability in Phase 3, are that it will be better than GSK's lupus drug Benlysta. Time to get into IMM.

[tradermichael] 11/12/2017 09:24

Data from this ongoing trial will be presented on 11th December in an oral presentation at the 59th annual meeting of the American Society of Hematology meeting in Atlanta.

“Oncology R&D at GSK is focused on developing medicines with transformational potential for patients and we are pleased that our investigational antibody-drug conjugate is the first BCMA targeting agent to receive Breakthrough Therapy and PRIME designation,” Axel Hoos, Senior Vice President Oncology R&D, at GlaxoSmithKline noted.

“GSK plans to rapidly advance clinical trials with this promising therapy, alone and in combination with other therapies, to further investigate how GSK2857916 could benefit patients with multiple myeloma. The monotherapy data that we have seen for GSK2857916 support its transformational potential and we look forward to working with regulators as we progress the development program,” Hoos added.

[tradermichael] 11/12/2017 09:18

Good article, thanks :

"Meanwhile, GSK is poised to publish .... a study on the effectiveness of its antibody treatment, code-named GSK 2857916, for multiple myeloma.

Analysts at Bank of America said they expected GSK’s study to show “very impressive early data” on the basis of a journal abstract the firm published ahead of the conference."

[philanderer] 10/12/2017 20:54

'AstraZeneca and GSK start fightback after big year for blood cancer treatments'

[polaris] 09/12/2017 12:33

Hi,

Anyone got the likely date for the response to Sandoz's ANDA for a generic Advair? It was submitted in June and, after the failures of Mylan and Hikma, I wonder just how long GSK will continue to enjoy exclusivity.

Advair brings in about 750M GBP per Q in sales, as sales have been falling since the 2013 peak, and GSKs own figures for 2017 expected in Xs of 1bn GBP, even in the case that a generic made it to market in the 2nd half. Most forward estimates had a generic to market by the end of 2017. That certainly will not happen, although an approval might well be given by the end of the year.

All the same, that is a whole boat load of cash that GSK continue to receive Q by Q while this resolves itself. I'd expect Sandoz and Hikma to make it to market sometime in the next 6-18 months (i think Mylan is least likely of the three to get FDA approval after the major) but Advair sales are not just going to go away, as pricing pressure will depend on how many generics and the timescales.

regards,

Paul

[ianood] 09/12/2017 11:10

gbh2 - yes, have appreciated a lot of your commentary over the years too!

[glavey] 09/12/2017 03:36

Very nice, but completely wrong forum.

[fangorn2] 08/12/2017 22:20

Haha yes posted here in error.

Thanks for letting me know.

Getting senile in my old age

[alphorn] 08/12/2017 20:08

Teva, the generic drug maker, is considering culling up to 10,000 posts. Should know more this month.

[gbh2] 08/12/2017 19:35

I use the IG share dealing ISA, only "Free" that one I know of so my interest in IG is quite diverse.

[woodhawk] 08/12/2017 17:56

I'm pretty much in the same situation as you, ianood. However, I tend to trade my SIPP and ISA accounts (tax free) and keep my longer term holdings in my sharedealing accounts (i.e. potentially taxable). I really like the IG setup; I also use them for spreadbetting. I'm trying to limit my tax, so may switch more of my (unsheltered) sharedealing to spreadbetting as I become more comfortable with it (as there's no tax on the profits). I'm not yet retired, but I have computer-based freelance work that means I can also trade shares all day if I wish.

[gbh2] 08/12/2017 17:52

I've being seening your user name for many years ianood so I guess we're in a similar position when you write "(that time of life!)"

Long term holdings are 6 to 24 months & Spread betting is simply for the rush :))

[ianood] 08/12/2017 17:31

Woodhawk,I wear both hats, the SIPP & ISA accounts tend to be buy and hold (that time of life!) then I use an IG index A/C for trading. However I am finding myself more driven by the buy and hold mentality of Terry Smith, particularly for income. Must admit the IG account still gives me a buzz!

[woodhawk] 08/12/2017 09:50

I'm of the same mind, gbh2. I like to trade, but happy to fall back on a decent divi
if, or while, any temporary setback occurs. I've done very well buying the dips on GSK over the past few years and I doubt it will be any different this time.

[gbh2] 08/12/2017 09:41

Agree it's good to trade (for me a decent 5%+ capital gain) is often the catalyst, especially as I'm not a long term holder in anything these days.

[woodhawk] 08/12/2017 09:28

ianood,

Perhaps I having more of a trading mentality?